{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:47Z","timestamp":1786984427213,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J500343\/1"],"award-info":[{"award-number":["MR\/J500343\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PA 815\/2-1"],"award-info":[{"award-number":["PA 815\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tenovus Scotland","award":["T15\/38"],"award-info":[{"award-number":["T15\/38"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["ISSF 105621\/Z\/14\/Z"],"award-info":[{"award-number":["ISSF 105621\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RER","award":["101788\/Z\/13\/Z"],"award-info":[{"award-number":["101788\/Z\/13\/Z"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.antiviral.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T20:17:27Z","timestamp":1508012247000},"page":"79-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice"],"prefix":"10.1016","volume":"150","author":[{"given":"Andri","family":"Vasou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-5790","authenticated-orcid":false,"given":"Janina","family":"Narloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe O.","family":"Gage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-3856","authenticated-orcid":false,"given":"Marie-Anne","family":"Rameix-Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"El\u00e9ou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-407X","authenticated-orcid":false,"given":"Michael","family":"Nevels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.10.012_bib1","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/jvi.76.5.2159-2167.2002","article-title":"Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha\/beta and gamma interferons","volume":"76","author":"Andrejeva","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib2","first-page":"173","article-title":"Respiratory syncytial virus mechanisms to interfere with type 1 interferons","volume":"372","author":"Barik","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mib.2016.05.015","article-title":"Innate immune evasion strategies of DNA and RNA viruses","volume":"32","author":"Beachboard","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00430-015-0397-y","article-title":"The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains","volume":"204","author":"Buscher","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib5","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1128\/JVI.79.17.11467-11475.2005","article-title":"Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53\/p21-mediated growth arrest response","volume":"79","author":"Castillo","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2010.08.008","article-title":"Heterocellular induction of interferon by negative-sense RNA viruses","volume":"407","author":"Chen","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.012_bib7","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.bmcl.2015.04.073","article-title":"Discovery of beta-D-2'-deoxy-2'-alpha-fluoro-4'-alpha-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases","volume":"25","author":"Clarke","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2017.10.012_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2017.10.012_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/10430340252898984","article-title":"High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter","volume":"13","author":"Demaison","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.antiviral.2017.10.012_bib10","first-page":"951","article-title":"Danoprevir, a small-molecule NS3\/4A protease inhibitor for the potential oral treatment of HCV infection","volume":"11","author":"Deutsch","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2017.10.012_bib11","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1128\/JVI.73.12.9928-9933.1999","article-title":"The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation","volume":"73","author":"Didcock","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib12","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3390\/v4112973","article-title":"Multifunctional nature of the arenavirus RING finger protein Z","volume":"4","author":"Fehling","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2017.10.012_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4030023","article-title":"Viral inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists","volume":"4","author":"Fleming","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2017.10.012_bib14","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/AAC.00134-08","article-title":"Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay","volume":"52","author":"Fukui","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.012_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/1087057116656314","article-title":"Identification of novel inhibitors of the type I interferon induction pathway using cell-based high-throughput screening","volume":"21","author":"Gage","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.antiviral.2017.10.012_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2017.10.012_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1099\/vir.0.2008\/004606-0","article-title":"The multifunctional NS1 protein of influenza A viruses","volume":"89","author":"Hale","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib19","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1220098110","article-title":"STAT2 deficiency and susceptibility to viral illness in humans","volume":"110","author":"Hambleton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.10.012_bib20","doi-asserted-by":"crossref","first-page":"e1005748","DOI":"10.1371\/journal.ppat.1005748","article-title":"Human cytomegalovirus immediate-early 1 protein rewires upstream STAT3 to downstream STAT1 signaling switching an IL6-type to an IFNgamma-like response","volume":"12","author":"Harwardt","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2017.10.012_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/viro.2002.1738","article-title":"Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling","volume":"303","author":"He","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.012_bib22","doi-asserted-by":"crossref","first-page":"11723","DOI":"10.1128\/JVI.01145-06","article-title":"The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation","volume":"80","author":"Hilton","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.it.2015.01.004","article-title":"Interferons and viruses: an evolutionary arms race of molecular interactions","volume":"36","author":"Hoffmann","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib24","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1128\/AAC.00399-13","article-title":"Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations","volume":"57","author":"Kalkeri","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.012_bib25","doi-asserted-by":"crossref","first-page":"12854","DOI":"10.1128\/JVI.01164-09","article-title":"Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2","volume":"83","author":"Krauss","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib26","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.44.3.688-692.2000","article-title":"A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates","volume":"44","author":"Landry","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.012_bib27","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1172\/JCI72948","article-title":"RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction","volume":"124","author":"Liesman","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2017.10.012_bib28","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1128\/JVI.79.14.9315-9319.2005","article-title":"Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha\/beta interferon responsiveness","volume":"79","author":"Lo","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib29","doi-asserted-by":"crossref","first-page":"17234","DOI":"10.1073\/pnas.0407933101","article-title":"Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation","volume":"101","author":"Nevels","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.10.012_bib30","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1073\/pnas.0600007103","article-title":"A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling","volume":"103","author":"Paulus","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.10.012_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/vir.0.80263-0","article-title":"In vitro and in vivo specificity of ubiquitination and degradation of STAT1 and STAT2 by the V proteins of the paramyxoviruses simian virus 5 and human parainfluenza virus type 2","volume":"86","author":"Precious","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2005.09.009","article-title":"Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction","volume":"344","author":"Ramaswamy","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.012_bib33","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/ncomms6104","article-title":"Visualizing the replication of respiratory syncytial virus in cells and in living mice","volume":"5","author":"Rameix-Welti","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2017.10.012_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib35","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1073\/pnas.94.7.3341","article-title":"Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate \"hit-and-run\" oncogenic transformation in cooperation with the adenovirus E1A proteins","volume":"94","author":"Shen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.10.012_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1099\/vir.0.83286-0","article-title":"Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40\/E","volume":"89","author":"Sinzger","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib37","doi-asserted-by":"crossref","first-page":"e112014","DOI":"10.1371\/journal.pone.0112014","article-title":"Inhibitors of the interferon response enhance virus replication in vitro","volume":"9","author":"Stewart","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.10.012_bib38","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Immediate-early viral gene regulation and function","author":"Stinski","year":"2007"},{"key":"10.1016\/j.antiviral.2017.10.012_bib39","doi-asserted-by":"crossref","first-page":"9682","DOI":"10.1128\/JVI.00715-09","article-title":"Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways","volume":"83","author":"Swedan","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib40","doi-asserted-by":"crossref","first-page":"e1002444","DOI":"10.1371\/journal.ppat.1002444","article-title":"A novel human cytomegalovirus locus modulates cell type-specific outcomes of infection","volume":"7","author":"Umashankar","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2017.10.012_bib41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.mib.2010.05.009","article-title":"Viral tricks to grid-lock the type I interferon system","volume":"13","author":"Versteeg","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib42","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.10.012_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coi.2016.06.009","article-title":"Innate immunity against hepatitis C virus","volume":"42","author":"Xu","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2017.10.012_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.virol.2015.07.016","article-title":"Respiratory syncytial virus nonstructural proteins 1 and 2 are crucial pathogenic factors that modulate interferon signaling and Treg cell distribution in mice","volume":"485","author":"Yang","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.012_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217304059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217304059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T18:45:24Z","timestamp":1603133124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217304059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":45,"alternative-id":["S0166354217304059"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.012","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}